Encapsulated Living Cells For Diabetes: The Final Push?
Lilly has linked up with US biotech Sigilon Therapeutics to develop encapsulated cell therapies for diabetes, a second "living therapeutics" approach to the condition to attract funding in the past six months.
You may also be interested in...
Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.